Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by EternalPonzion Feb 17, 2020 3:30pm
178 Views
Post# 30699892

RE:RE:US Market hates the optics; shareholders suffer

RE:RE:US Market hates the optics; shareholders suffer
SEC guaranteed to investigate if suspected insider trading complaints are filed. I was waiting to hear what they would say and what questions would be asked before pulling the trigger on filing a complaint. Insider trading cannot/must not be tolerated. The short sellers acted on insider info, I have no doubt of that. No one in their right mind would short a company on the verge of breaking out. No one in their right mind could realistically believe that the drug arm would fail outright or the placebo arm would give extraordinary results. Yet we are to believe some were smart enough to anticipate one of those to outcomes would happen. They cheated and we know it. Now it needs to be proven. I will file both SEC and OSC complaints asking that the unusual trading activities be investigated and all short selling, especially positions taken from mid Dec to mid Jan be investigated. More the merrier, so if you are perturbed by all the games then file a complaint.
Bullboard Posts